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Abstract
Background Drug-induced torsades de pointes (TdP) and
related clinical entities represent a current regulatory and
clinical burden.
Objective As part of the FP7 ARITMO (Arrhythmogenic
Potential of Drugs) project, we explored the publicly
available US FDA Adverse Event Reporting System (FA-
ERS) database to detect signals of torsadogenicity for an-
tipsychotics (APs).
Methods Four groups of events in decreasing order of
drug-attributable risk were identified: (1) TdP, (2) QT-
interval abnormalities, (3) ventricular fibrillation/tachy-
cardia, and (4) sudden cardiac death. The reporting odds
ratio (ROR) with 95 % confidence interval (CI) was
calculated through a cumulative analysis from group 1 to 4.
For groups 1?2, ROR was adjusted for age, gender, and
concomitant drugs (e.g., antiarrhythmics) and stratified for
AZCERT drugs, lists I and II (http://www.azcert.org, as of
June 2011). A potential signal of torsadogenicity was
defined if a drug met all the following criteria: (a) four or
more cases in group 1?2; (b) significant ROR in group
1?2 that persists through the cumulative approach;
(c) significant adjusted ROR for group 1?2 in the stratum
without AZCERT drugs; (d) not included in AZCERT lists
(as of June 2011).
Results Over the 7-year period, 37 APs were reported in
4,794 cases of arrhythmia: 140 (group 1), 883 (group 2),
1,651 (group 3), and 2,120 (group 4). Based on our criteria,
the following potential signals of torsadogenicity were
found: amisulpride (25 cases; adjusted ROR in the stratum
without AZCERT drugs = 43.94, 95 % CI 22.82–84.60),
cyamemazine (11; 15.48, 6.87–34.91), and olanzapine
(189; 7.74, 6.45–9.30).
Conclusions This pharmacovigilance analysis on the
FAERS found 3 potential signals of torsadogenicity for
drugs previously unknown for this risk.
1 Introduction
Drug-induced cardiac ventricular arrhythmias represent a
major safety concern, both on regulatory and clinical
grounds [1, 2]. Torsades de pointes (TdP) is a specific form
of ventricular arrhythmia very frequently attributable to
drug administration. Together with its surrogate QT pro-
longation, TdP has caused a variety of drug withdrawals
and/or restrictions of use (e.g., haloperidol, sertindole, and
astemizole) in past decades, especially for noncardiovas-
cular drugs [3]. In addition, a long list of warnings of TdP
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risk from regulatory agencies has begun to accrue, resulting
in a reduction of therapeutic alternatives in the prescribers’
toolkit. From the clinical standpoint, TdP frequently ter-
minates spontaneously, causing syncope, but can some-
times degenerate into ventricular fibrillation with cardiac
arrest and sudden cardiac death (SCD) if not resuscitated
[4]. The point at which the physician observes an evolving
arrhythmic event (such as TdP) therefore influences how
the event will be described and reported. Hence, composite
clinical endpoints are needed to fully explore the range of
drug-associated TdPs [5]. Moreover, a number of risk
factors for TdP occurrence have been identified (e.g.,
congenital long QT syndrome, heart failure, electrolyte
balance impairment, multiple drug therapies) and physi-
cians are requested to prioritize patient safety by selecting
the safest therapy among the available options [6].
Although a number of strategies (both clinical and
preclinical) have been proposed, the assignment of the
proarrhythmic risk of drugs is still far from established,
because of the lack of predictive value of each approach
[7]. The attempt to provide a torsadogenic score to each
drug by knowledge integration of heterogeneous evidence
represents the ultimate goal of the ARITMO (Arrhythmo-
genic Potential of Drugs) project [8]. As part of this con-
sortium, spontaneous reporting systems emerged as a
cornerstone for timely detection of signals (previously
unknown drug–event associations or increasing the fre-
quency of known adverse drug reactions [ADRs]), which
deserve validation and risk quantification through different
sources such as healthcare databases. The importance of
pharmacovigilance analyses has been clearly underlined by
several studies that showed that case report/case series
represented the most important source of evidence for drug
withdrawals in Europe and the US [9].
Although several postmarketing studies have been con-
ducted to assess the risk of QT prolongation, TdP, ven-
tricular fibrillation, and SCD with non-anti-arrhythmic
drugs [10–16], to the best of our knowledge, no pharma-
covigilance analyses have systematically addressed the
torsadogenic potential of antipsychotics (APs). The interest
for this therapeutic class has strongly increased in the past
two decades for several reasons: on the one hand, the
epidemiological burden of the psychoses and the related
innovation in diagnostic procedures for early recognition;
on the other hand, the availability of new drugs with pos-
sibly better benefit–risk profiles compared with the older,
first-generation compounds and the consequent increase in
drug consumption throughout all age groups, ethnic groups,
and approved indications [17–20]. The rapid changes in the
uptake of these drugs require adequate monitoring of actual
adverse effects in the population, while spontaneous
reporting represents a ready-to-use source of data to be
analyzed for an early and timely identification of risks.
In this study, we explored the US FDA Adverse Event
Reporting System (FAERS) to detect signals of increased
torsadogenic risk for APs. By virtue of its large population
coverage (including all US reports and serious/unexpected
ADRs from non-US countries) and free availability (pro-
viding public access from 2004), the FAERS is an attrac-
tive source to explore rare ADRs such as TdP [21, 22].
2 Methods
2.1 Data Source and Processing
Data were obtained from the publicly accessible FAERS
database (first quarter of 2004 through fourth quarter of
2010), which is a computerized information system where
healthcare professionals and consumers send adverse event
reports voluntarily through the MedWatch program [23].
The system includes all serious and unlabelled spontaneous
reports from the USA and non-US countries (submission
required by manufacturers), and nonserious reports only
from the USA [24].
Data submitted to the FAERS database are structured in
different files, generating specific tables that are linked to
each other by an ‘ISR number’. Each ISR number identifies
a case–drug pair and may indicate an initial or a follow-up
status of the report. More case–drug pairs can be included
in a unique FAERS case, identified by a ‘case number’.
The following files/tables were analyzed:
A. DEMO: demographic characteristics (patient ‘age’,
‘gender’, ‘reporter country’, and ‘event date’);
B. DRUG: reported medications with their assigned role
code (‘primary suspect drug’, PS; ‘secondary suspect
drug’, SS; ‘interacting’, I; ‘concomitant’, C). The analysis
was restricted to reports where APs were recorded as sus-
pect or interacting. Information on concomitant drugs was
used to identify potential confounders/effect modifiers to
adjust or stratify disproportionality analysis (see below).
C. REACTION: ADRs coded by the standardized
Medical Dictionary for Regulatory Activities (MedDRA),
the international medical terminology developed under the
auspices of the International Conference on Harmonization
of Technical Requirements for Registration of Pharma-
ceuticals for Human Use (ICH). The full list of MedDRA
preferred terms (PTs) used for search strategy is shown as
supplementary material in Table S2;
D. OUTCOME: death, life-threatening, hospitalization,
or other. This information on the seriousness of the disease
was used to identify different subgroups within outcomes
of interest (see below).
Data mining of the FAERS requires complex data pro-
cessing to obtain the final dataset; in particular, an ad hoc
drug mapping, duplicate detection and removal as well as
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management of missing data. These technical issues are
described in detail elsewhere [25]. In summary, this mapping
approach allowed allocation of a substance name to about
90 % of all records in the entire database. The fraction of
missing data varied widely among data files (e.g., 8 % for
gender, 34 % for age). In this study, we first imputed missing
values in the DEMO file based on the degree of similarity
between two records; we then excluded reports with missing
information on age and gender, and, finally, performed a
de-duplication approach based on the following key field: age,
gender, event date, and reporter’s country. This multistep
process not only ensures a minimum level of quality of
spontaneous reports, but also is warranted to allow adjustment
for demographic factors in disproportionality (see below).
2.2 Case Definition and Coding
Because of the heterogeneous nature of drug-induced TdP,
composite clinical endpoints are needed to capture as many
cases as possible associated with drug exposure [5].
Therefore, a multidisciplinary panel within the ARITMO
consortium (i.e., cardiologists, pharmacoepidemiologists,
and pharmacovigilance experts) reached consensus on
defining four groups of events in decreasing order of drug-
attributable risk for TdP. The groups were: (1) TdP; (2) QT
interval abnormalities; (3) ventricular fibrillation/tachycar-
dia; and (4) SCD. Within each group, different subgroups
were identified based on the seriousness of the outcomes;
that is, whether the event caused death or life-threatening
events. These groups allow both evaluation of single events
per se and combined analyses of groups of events through a
cumulative approach (i.e., a single case report of interest
can be classified only in one group based on the following
order: 1 [ 2 [ 3 [ 4). Details on outcome definition are
provided in the supplementary material (Table SI). This
case definition was created by building on the already
existing standardized MedDRA query (SMQ), namely
TdT-QT prolongation, which is based on a ‘narrow’ strat-
egy (including a core of medical concepts specific for TdP/
QT prolongation) and a ‘broad’ search scope (including
nonspecific terms such as SCD). As a matter of fact, all PTs
of the SMQ were considered, with the addition of new
potentially useful terms (e.g., QT-interval shortening [26,
27]). Moreover, the seriousness of the event was analyzed to
distinguish different subgroups and remove nonspecific
clinical entities such as non-life-threatening syncope with a
neurological cause. For a complete list of MedDRA codes
(version 13.0), see supplementary Table SII.
2.3 Data Analysis
First, a case listing was generated with the AP and the
number of cases by type of event. Second, we applied the
case/noncase disproportionality analysis to the four groups
of events; cases were represented by reports of arrhythmias
according to PTs of MedDRA coding, whereas noncases
were defined as all other reports (i.e., those without such
PTs). Disproportionality analysis was performed by cal-
culating the reporting odds ratio (ROR), with the corre-
sponding 95 % confidence interval (CI). Disproportionality
was formally defined when the lower limit of the 95 % CI
was [1, with [3 cases [28]. The ROR was first calculated
by progressively aggregating the events from 1 to 4 (i.e.,
cumulative analysis). Second, the disproportionality
approach was refined in light of the clinical setting in
which TdP usually occurs.
When more than one outcome of interest was listed in a
single report (e.g., TdP and QT prolongation), the case was
considered once by assigning the priority to the most
specific outcome for TdP (i.e., TdP [ QT abnormali-
ties [ ventricular fibrillation/tachycardia [ SCD).
Because the role of other risk factors cannot be disre-
garded in the genesis of TdP (the multihit hypothesis
implying the so-called reduced repolarization reserve [29]),
the following approach was carried out. The main known
factors influencing association between drug and TdP were
taken into account to perform separate univariate regres-
sions: age, gender, use of Class I/III antiarrhythmic drugs
as a proxy of already diagnosed arrhythmia (ATC code:
C01B), use of drugs with cardiovascular indications (i.e.,
digitalis, C01A; diuretics, C03; beta blockers, C07; cal-
cium channel blockers, C08; ACE inhibitors/ARBs, C09)
as a proxy of heart disease, and use of drugs known for
their torsadogenic potential (reference source: lists I and II
of the Arizona CERT [30], downloaded in the version
available as of June 2011).
The concomitant presence of AZCERT drugs emerged
as an effect modifier and was therefore used for stratifi-
cation, whereas other covariates were regarded as con-
founding factors and were used to adjust the ROR
according to the Mantel–Haenszel method.
A potential signal of torsadogenicity was defined if a
drug met all the following criteria:
• at least 4 cases in group 1?2;
• significant disproportionality in group 1?2 that persists
through the cumulative approach;
• significant disproportionality in group 1?2 (ROR
adjusted for confounders) in the stratum without
AZCERT drugs (effect modifier);
• not included in the AZCERT lists (downloaded in the
version available as of June 2011).
As a third step, the ROR was calculated within APs.
This means to compare the reporting of a given drug with
other agents belonging to the same therapeutic class (e.g.,
haloperidol versus all other APs). To this end, the analysis
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was run using a subset of data at the ATC level 3 (N05A).
This approach allowed for mitigation of potential bias such
as ‘confounding by indication’, which should be consid-
ered because patients with psychosis have an increased
likelihood of SCD. Restriction of the analysis to the
pharmacological class of interest may be considered as a
sensitivity analysis and allows for investigation of potential
intraclass variations in terms of risk. All the analyses were
performed using the statistical package SPSS (version 19.0,
IBM SPSS Software, Armonk, NY, USA).
3 Results
3.1 Descriptive Analysis
Over the 7-year period, 2,131,688 spontaneous reports
were retrieved after removal of duplicates and multiple
records. The outcomes of interest according to case defi-
nition (see ‘Methods’ and Table S1) were reported in
62,848 cases (Fig. 1); 5,802 of these reports contained at
least one AP drug. Among the considered outcomes, SCD
(group 4a) and nonserious ventricular tachycardia (group
3c) were the most frequently reported outcomes, and APs
were mentioned in the 8–9 % of these. On the other hand,
TdP (group 1) and symptomatic QT abnormalities (group
2a) were less frequently reported outcomes both for the
overall FAERS reports (1,770 and 1,075 cases, respec-
tively) and for the AP reports (168 and 241). Notably, APs
were reported in 9 % of TdP cases and in 22 % of symp-
tomatic QT abnormalities.
Most of the cases associated with APs occurred in
women, especially for group 1 (60 %) and group 2 (56 %).
Patients younger than 65 years of age were the most fre-
quently represented: 66, 80, 88, and 83 % of cases (groups
1, 2, 3, and 4, respectively). Physicians submitted 46 % of
TdP cases (group 1), 52 % of group 2 cases, and 46 % of
the cases in groups 3 and 4, respectively. The USA was the
reporter country in 48, 29, 26, and 44 % of the ARITMO
cases (groups 1, 2, 3, and 4, respectively).
Table 1 shows the number of cases grouped by outcome
for each considered agent. Overall, 37 different APs were
reported in cases of cardiac arrhythmia: quetiapine (1,120
cases), clozapine (1,078), and olanzapine (901) were the
most frequently reported. By considering only group 1
(TdP), 7 drugs were reported in at least 4 cases with the
following ranking: haloperidol (40 cases), ziprasidone (29),
quetiapine (25), risperidone (21), olanzapine (8), droperidol
(6), and amisulpride (4). By extending the selection of cases
to QT abnormalities (group 1 ? group 2 outcomes), 20 APs
reached 4 cases: olanzapine (189 cases), quetiapine (186),
and clozapine (178) were the most frequently reported.
2,131,688
Total FDA cases
At least a valid drug name
in suspect or interacting drugs
2,047,519
62,848
With ARITMO outcomes
5,802At least an
antipsychotic agent
1,770 4,405 24,215 32,458
50,871
1,472 3,511 19,899 25,989
168 1,118 1,974 2,542
4,794
140 883 1,651 2,120
Both age and gender not null Both age and gender not null
GROUP 1 GROUP 2 GROUP 3 GROUP 4 GROUP 1 GROUP 2 GROUP 3 GROUP 4
Fig. 1 Flowchart describing data-mining approach to allocate cases of interest according to relevant case definition. ARITMO Arrhythmogenic
Potential of Drugs
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3.2 Disproportionality Analyses
Table 2 provides the results of disproportionality analysis
(crude ROR) obtained by combining groups through a
progressive cumulative approach (1?2?3?4). Among 37
analyzed APs, 5 drugs showed disproportionality in all
steps of the cumulative analysis: amisulpride, droperidol,
haloperidol, risperidone, and ziprasidone. At the second
step (groups 1?2a), 5 drugs appeared: cyamemazine,
levomepromazine, olanzapine, quetiapine, and zuclopen-
tixole; and 7 drugs at the third (groups 1?2): bromperidol,
chlorpromazine, chlorprothixene, clozapine, fluphenazine,
pimozide, and prothipendyl. Notably, for all APs with
significant ROR in group 1 or 2, disproportionality per-
sisted throughout all remaining groups. However, the
strength of the ROR, in terms of absolute values, increases
from group 1 to 2 and progressively declines when moving
from group 2 to 4.
Table 1 Distribution of cases according to relevant outcomes (see text for details)
Antipsychotic 1 2a 2b 3a 3b 3c 4a 4b Total
Acepromazine 1 2 1 4
Amisulpride 4 4 (1) 17 (1) 3 (4) 14 (3) 18 (3) 1 61
Aripiprazole 3 8 (1) 35 (1) 4 15 (1) 86 (5) 102 (9) 23 (5) 276
Asenapine 2 3 2 2 (1) 9
Bromperidol 1 6 2 3 3 (1) 15
Chlorpromazine 1 1 12 3 5 19 (1) 35 (1) 7 (5) 83
Chlorprothixene 1 2 1 (1) 1 (1) 4 (1) 14 (2) 3 (3) 1 (1) 27
Clozapine 1 16 161 (1) 9 (1) 88 (2) 346 (48) 356 (30) 101 (32) 1,078
Cyamemazine 7 4 10 (2) 8 (1) 18 (4) 4 51
Droperidol 6 1 (2) 3 (1) 1 (2) 7 (2) 7 (1) 4 (5) 1 (1) 30
Flupentixol 2 1 (1) 2 4 (1) 2 11
Fluphenazine 1 7 3 6 12 (1) 1 (4) 30
Haloperidol 40 27 (8) 58 (2) 12 (11) 40 (27) 68 (7) 96 (35) 23 (18) 364
Levomepromazine 1 4 1 1 (1) 3 (1) 11 20 (6) 4 (3) 45
Levosulpiride 1 1
Loxapine 2 1 4 (3) 6 9 (6) 3 25
Melperone 1 1 3 5
Olanzapine 8 59 (4) 122 (1) 17 (7) 71 (18) 167 (13) 387 (42) 70 (56) 901
Paliperidone 3 8 1 (1) 3 (1) 35 (2) 6 1 57
Perazine 7 1 8
Periciazine 7 7
Perphenazine 1 3 7 (1) 2 13
Pimozide 3 (3) 13 (1) 2 3 (3) 1 (2) 22
Pipamperone 1 (1) 1 7 5 (1) 2 (2) 16
Pipotiazine 1 1
Prochlorperazine 1 2 4 16 4 (1) 27
Promazine 2 1 3 (1) 2 8
Prothipendyl 1 5 1 8 (1) 3 1 (1) 19
Quetiapine 25 44 (10) 117 (7) 27 (14) 79 (18) 283 (26) 468 (49) 77 (38) 1,120
Risperidone 21 31 (6) 99 (3) 17 (5) 40 (15) 183 (16) 199 (30) 47 (27) 637
Sulpiride 3 10 4 (1) 4 2 23
Sultopride 1 (1) 3 (1) 4
Tiapride 1 1 5 1 8
Trifluoperazine 6 1 7
Ziprasidone 29 37 (6) 101 (13) 4 (12) 14 (15) 34 (11) 96 (32) 13 (16) 328
Zotepine 2 6 1 (1) 9
Zuclopenthixol 5 1 3 (1) 3 (1) 10 (3) 22
Sertindole (never marketed) and thioridazine (no longer available in the USA) are not shown. Only antipsychotics with at least one case are
shown. Data in parentheses show cases already counted in preceding outcomes (mutually exclusive approach). See Methods section for details
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Table 3 shows the results of disproportionality analyses,
stratified and adjusted for covariates (see ‘Methods’), per-
formed on 29 APs with cases of TdP/QT abnormalities. Six
agents showed disproportion in all different data-mining
approaches (both crude, stratified, and adjusted within
strata): amisulpride, clozapine, droperidol, haloperidol,
risperidone, ziprasidone. For 4 additional APs (chlor-
promazine, cyamemazine, olanzapine, and quetiapine),
disproportion found by crude ROR persisted only in the
stratum without concomitant AZCERT drugs, also after
adjustment. Aripiprazole and paliperidone showed signifi-
cant disproportion only in the stratum without concomitant
AZCERT drugs, before and after the adjustment.
Based on previously described criteria (see Table 4), the
following potential signals of torsadogenicity were found:
amisulpride (25 cases; adjusted ROR in the stratum without
AZCERT drugs 43.94, 95 % CI 22.82–84.60), cyamema-
zine (11; 15.48, 6.87–34.91), and olanzapine (189; 7.74,
6.45–9.30).
When the disproportionality was calculated intraclass
(i.e., by considering only reports where at least one AP was
recorded, Table 5), a significant disproportion was found
through all approaches for only three agents: amisulpride,
haloperidol, and ziprasidone. Chlorpromazine, cyamema-
zine, and olanzapine showed disproportion only in the
strata without concomitant AZCERT drugs (before and
after adjustment for covariates).
4 Discussion
The FAERS from 2004 up to December 2010 contained
case reports of cardiac arrhythmia related to 39 AP
agents. Based on our criteria to define potential signals
of torsadogenicity, the following APs emerged: amisul-
pride, cyamemazine, and olanzapine. The case-by-case
evaluation of reports (e.g., number of concomitant drugs,
information on dechallenge, time to onset, where avail-
able) found no elements in causality assessment against
this hypothesis. Notably, these agents represent old drugs
with different marketing penetration: a high and very
widespread use for olanzapine, a lower but considerable
consumption in many Countries for amisulpride and a
marketing authorization limited to a few countries for
cyamemazine (only in France and Portugal). Remarkably,
AZCERT lists have been updated after our analysis, and,
in fact, only recently have amisulpride and olanzapine
been added to AZCERT lists III and II, respectively.
Amisulpride is the only AP categorized in this group
with ‘conditional risk of TdP’: considering that dispro-
portion persisted in the intraclass analysis, it could also
be considered for inclusion in higher risk lists. In our
opinion, olanzapine is now included in the appropriate
risk category, similar to many other second-generation
APs.
Our study should be interpreted with caution, especially
in light of inherent limitations affecting spontaneous
reporting systems, which cannot be used to provide inci-
dence or to quantify risk due to under-reporting and lack of
exposure data, respectively. In the FAERS, data distortion
may occur at two levels: individual records (e.g., quality
and completeness of the reported information that com-
promise the causality assessment, duplicates, errors in drug
codification, etc.) and the overall sample (e.g., lack of
nonserious events for drugs outside the US market, market
penetration of drugs). Nonetheless, all technical issues
have been considered in this analysis. In addition, several
well-known external factors may affect reporting; for
example, notoriety bias, the Weber effect, and product age
[31–34]. In this respect, with only a few exceptions (ari-
piprazole, asenapine, and paliperidone), APs have long
been in use and therefore the impact of these factors is
assumed to be limited.
Notwithstanding the aforementioned limitations, our
study found three potential torsadogenic signals that should
be taken into account when assessing the risk–benefit
profile of APs: the available evidence suggests similar
torsadogenic profiles for first- and second-generation
agents [35], as well as no significant difference in their
effectiveness [36]. Our findings are also in line with a
recent pharmacovigilance analysis of the WHO_Vigibase,
which revealed no difference in the cardiac safety profile
among haloperidol, olanzapine, and quetiapine [37].
Preclinical data on amisulpride, cyamemazine, and
olanzapine (mainly in vitro studies on human Ether-a`-go-
go Related Gene [hERG] blocking potency) showed only
minor inhibition of hERG K? channels compared with
haloperidol and thioridazine, and indicate only a low tor-
sadogenic potential in humans [38, 39]. For cyamemazine,
similar hERG channel affinities were demonstrated both
for the parent compound and the relevant active metabo-
lites [40, 41]. The hERG blocking liability of olanzapine
was confirmed to be theoretically low also in the context of
pharmacokinetic data such as myocardial distribution [42].
Notably, the occurrence of TdP-related events in amisul-
pride recipients could be a specific concern of the overdose
setting, a clinical scenario carrying increased risk of
torsadogenicity [43]. These data together with the lack of
dedicated thorough QT studies strengthen the importance
of postmarketing surveillance to detect safety issues that
may be missed during the premarketing phase because of
the imperfect predictivity of in vitro/in vivo studies.
Although no signal was found for more recently mar-
keted APs, aripiprazole and paliperidone deserve appro-
priate discussion because they are gaining increasing
marketing penetration. Aripiprazole, first marketed in 2002
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in the USA, is currently recommended for the treatment of
schizophrenia, for the treatment of manic or mixed epi-
sodes associated with bipolar I disorder, and for preventing
the recurrence of mood episodes during longer-term ther-
apy. More recently, aripiprazole has been approved as an
adjunctive treatment for major depressive disorder [44].
Moreover, it is considered the safer alternative in patients
with risk factors for QT prolongation [45, 46]. A recent
meta-analysis also showed a lower impact on QT interval
by aripiprazole in comparison with other second-genera-
tion APs [47]. By contrast, our analysis found that aripip-
razole was reported in 46 cases of TdP/QT abnormalities
with significant disproportionality in the two strata without
AZCERT drugs, although the intraclass ROR was not
Table 2 Cumulative reporting odds ratio (ROR)
Antipsychotic 1 1?2a 1?2 1?2?3a 1?2?3a?3b 1?2?3 1?2?3?4a 1?2?3?4
Acepromazine 2.14
Amisulpride 8.60* 10.67* 18.72* 12.96* 8.69* 7.09* 5.45* 5.00*
Aripiprazole 0.59 1.32 0.99 0.77 0.93 0.79 0.78
Asenapine 0.35 0.25 0.29
Bromperidol 80.51* 55.76* 47.80* 40.52* 32.98* 29.64*
Chlorpromazine 4.86* 4.11* 3.17* 3.16* 3.12* 3.11*
Chlorprothixene 8.62* 7.54* 8.40* 13.11* 7.73* 7.31*
Clozapine 0.66 3.77* 2.73* 2.40* 2.91* 2.37* 2.38*
Cyamemazine 7.73* 6.49* 4.49* 5.24* 3.82* 3.28* 3.24*
Droperidol 30.78* 22.13* 17.11* 13.15* 13.54* 10.35* 6.25* 5.87*
Flupentixol 3.15 2.78* 2.64* 2.98*
Fluphenazine 6.62* 4.59* 3.78* 3.10* 2.78* 2.60*
Haloperidol 7.31* 7.55* 7.57* 5.75* 4.44* 3.23* 2.32* 2.24*
Levomepromazine 7.34* 4.67* 3.79* 3.24* 3.67* 3.90* 3.92*
Levosulpiride
Loxapine 3.63* 3.61* 3.25* 3.38*
Melperone 6.86* 3.44* 3.09*
Olanzapine 0.44 2.29* 3.47* 2.61* 2.09* 1.75* 1.70* 1.67*
Paliperidone 1.35 1.02 0.76 1.33* 0.75 0.68
Perazine 6.83* 4.00* 3.59*
Periciazine 17.49* 9.04* 4.53* 4.07*
Perphenazine 1.35 1.97* 2.12*
Pimozide 54.35* 37.63* 22.30* 13.39* 8.25* 7.90*
Pipamperone 2.90* 2.35* 2.45*
Pipotiazine
Prochlorperazine 0.99 1.71* 1.83*
Promazine 6.27* 3.14* 3.95*
Prothipendyl 14.11* 11.54* 6.84* 8.33* 5.21* 5.01*
Quetiapine 0.89 1.51* 2.18* 1.72* 1.41* 1.45* 1.35* 1.31*
Risperidone 1.61* 2.46* 3.84* 2.96* 2.17* 2.16* 1.67* 1.63*
Sulpiride 3.62* 2.29* 2.27*
Sultopride 9.77* 8.78*
Tiapride 1.75 1.82
Trifluoperazine 1.35 1.43
Ziprasidone 6.81* 9.65* 13.47* 9.52* 6.11* 3.77* 2.82* 2.65*
Zotepine 7.33* 7.73*
Zuclopenthixol 18.31* 11.72* 8.115* 7.425* 5.27* 5.37* 4.83*
ROR is provided only if applicable (i.e., at least 4 cases for the event of interest, see ‘Methods’ for details). Sertindole (never marketed) and
thioridazine (no longer available in the USA) are not shown.
* Statistically significant ROR
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significant. This may be easily explained by the fact that
the intraclass analysis was performed on a pharmacolog-
ical class of concern associated with a certain baseline
level of proarrhythmic risk, which may bias dispropor-
tionality. On the other hand, the relatively high number of
cases and the relevant disproportionality may result from
channelling of patients at risk (who receive aripiprazole
as a safer alternative according to guidelines). Although
our data require validation, caution is needed in vulner-
able patients: the risk for the patients must be balanced
against the benefit achieved in controlling their underlying
disease.
Table 4 Synopsis of criteria used to define signals of torsadogenicity
Antipsychotic At least 4
cases in
groups 1?2
Significant crude ROR for
groups 1?2 and throughout
the cumulative approach
Significant adjusted ROR for
groups 1?2 in the stratum
without AZCERT drugs
Not included in
AZCERT lists
(as of June 2011)
Acepromazine 9
Amisulpride 9 9 9 9
Aripiprazole 9 9 9
Asenapine 9
Bromperidol 9 9
Chlorpromazine 9 9 9
Chlorprothixene 9 9 9
Clozapine 9 9 9
Cyamemazine 9 9 9 9
Droperidol 9 9 9
Flupentixol 9
Fluphenazine 9 9 9
Haloperidol 9 9 9
Levomepromazine 9 9 9
Levosulpiride 9
Loxapine 9
Melperone 9
Olanzapine 9 9 9 9
Paliperidone 9 9
Perazine 9
Periciazine 9
Perphenazine 9
Pimozide 9 9
Pipamperone 9
Pipotiazine 9
Prochlorperazine 9
Promazine 9
Prothipendyl 9 9 9
Quetiapine 9 9 9
Risperidone 9 9 9
Sulpiride 9
Sultopride 9
Tiapride 9
Trifluoperazine 9
Ziprasidone 9 9 9
Zotepine 9
Zuclopenthixol 9 9 9
Sertindole (never marketed) and thioridazine (no longer available in the USA) are not shown
9 indicates that the drug fulfills relevant criterium
Antipsychotics and Torsadogenic Risk 475
Paliperidone is listed in AZCERT list II and its summary
of product characteristics describes a mild risk for QT
prolongation; in vitro studies showed a high potency of
K?-channel blockade, whereas the effect in a dedicated
thorough QT study was considered nonsignificant from a
regulatory standpoint and noninferior to quetiapine [48–
50]. The 11 cases together with disproportionality analysis
indicate that uncertainty persists on its torsadogenic risk. It
seems appropriate to continue monitoring paliperidone.
No firm conclusion can be drawn from our study
regarding asenapine, because of its very recent marketing
approval (2009 in the USA).
From a general regulatory viewpoint, the consensus
process in case definition resulted in a comprehensive
query, which can be utilized by regulators and researchers
when investigating the torsadogenic potential of a given
drug within a pharmacovigilance database. Although the
search strategy carries inherent limitations of spontaneous
reports (e.g., the inability to validate cases of SCD through
autopsy), the aim of our approach was to increase the
sensitivity of signal detection without substantially affect-
ing specificity; that is, to build on the existing rather than
replace the current SMQ.
Another important aspect pertains to the cumulative
approach in decreasing order of drug-attributable risk for
TdP. This approach may be of interest to refine signal
detection because disproportion may appear for a single
outcome. Notably, all APs with disproportionality in group
Table 5 Intraclass reporting odds ratio of torsades de pointes or QT abnormalities (group 1 ? group 2)
Antipsychotic ROR 95 % CI ROR1
a 95 % CI ROR0
b 95 % CI aROR1
a 95 % CI aROR0
b 95 % CI
Amisulpride 4.47 2.84–6.76 3.74 2.21–6.35 8.12 4.20–15.71 3.46 2.03–5.87 7.65 3.82–15.32
Aripiprazole 0.30 0.22–0.40 0.59 0.40–0.86 0.24 0.15–0.38 0.59 0.40–0.87 0.26 0.16–0.42
Asenapine n.a. n.a. n.a. n.a. n.a.
Bromperidol 19.16 6.76–48.13 18.98 7.29–49.44 n.a. 19.45 7.50–50.46 n.a.
Chlorpromazine 1.15 0.63–1.95 0.90 0.40–2.01 2.25 1.10–4.58 0.93 0.42–2.09 2.64 1.30–5.39
Chlorprothixene 2.05 0.55–5.42 n.a. n.a. n.a. n.a.
Clozapine 0.87 0.75–1.02 1.11 0.87–1.42 1.22 0.98–1.51 1.08 0.85–1.38 1.37 1.09–1.72
Cyamemazine 1.54 0.76–2.80 1.28 0.53–3.13 2.65 1.17–6.03 1.26 0.51–3.10 3.30 1.45–7.49
Droperidol 4.07 1.90–7.76 9.07 4.02–20.49 2.94 0.92–9.35 8.73 3.45–22.09 1.75 0.44–6.92
Flupentixol n.a. n.a. n.a. n.a. n.a.
Fluphenazine 1.57 0.67–3.16 2.43 0.99–5.99 n.a. 2.48 1.00–6.15 n.a.
Haloperidol 1.80 1.51–2.20 3.10 2.48–3.88 1.62 1.20–2.20 3.25 2.57–4.10 1.69 1.24–2.30
Levomepromazine 1.11 0.40–2.45 1.28 0.52–3.11 n.a. 1.24 0.51–3.00 n.a.
Levosulpiride n.a. n.a. n.a. n.a. n.a.
Loxapine n.a. n.a. n.a. n.a. n.a.
Olanzapine 0.79 0.68–0.93 0.81 0.63–1.03 1.35 1.08–1.70 0.77 0.61–0.99 1.49 1.18–1.88
Paliperidone 0.32 0.16–0.57 0.52 0.21–1.25 0.40 0.18–0.90 0.51 0.21–1.23 0.47 0.21–1.06
Pimozide 12.97 6.97–22.82 18.06 9.47–34.47 n.a. 17.1 9.04–32.37 n.a.
Pipamperone n.a. n.a. n.a. n.a. n.a.
Prochlorperazine n.a. n.a. n.a. n.a. n.a.
Promazine n.a. n.a. n.a. n.a. n.a.
Prothipendyl 3.56 1.20–7.61 n.a. n.a. n.a. n.a.
Quetiapine 0.47 0.40–0.54 0.43 0.35–0.54 0.77 0.61–0.96 0.43 0.35–0.54 0.82 0.65–1.03
Risperidone 0.89 0.75–1.06 1.24 0.98–1.58 1.10 0.86–1.40 1.14 0.89–1.45 1.09 0.85–1.40
Sulpiride n.a. n.a. n.a. n.a. n.a.
Sultopride n.a. n.a. n.a. n.a. n.a.
Tiapride n.a. n.a. n.a. n.a. n.a.
Ziprasidone 3.32 2.81–3.92 4.34 3.40–5.54 3.75 2.97–4.74 4.42 3.44–5.66 4.20 3.30–5.35
Zuclopenthixol 2.79 0.99–6.27 2.46 0.90–6.73 n.a. 2.32 0.85–6.37 n.a.
Sertindole (never marketed) and thioridazine (no longer available in the USA) are not shown.
aROR reporting odds ratio adjusted for confounder factors (see text for details), CI confidence interval, n.a. not applicable (number of cases\4),
ROR reporting odds ratio
a Stratum with concomitant AZCERT drugs (lists 1 and 2)
b Stratum without concomitant AZCERT drugs (lists 1 and 2)
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1 or 2 maintained significant ROR when groups 3 and 4
were added to the analysis. This indicates a good concor-
dance between more drug-attributable outcomes (TdP and
QT abnormalities) and more sensitive ones (ventricular
arrhythmia and SCD). In addition, the analysis of groups 3
and 4 may be useful for drugs with uncertain data on TdP;
for instance, due to the low number of cases, especially for
recent drugs (e.g., asenapine).
Concerning data processing, the analysis restricted to
the refined dataset (i.e., reports without missing data, see
Supplementary Table SIII) demonstrated that the adopted
criteria did not significantly affect results, but ensured a
minimum quality standard.
The role of concomitant drugs as effect modifiers/con-
founders has been carefully addressed and its importance in
the drug–event association clearly emerged, as also
recently demonstrated by Tatonetti et al. [51] through a
data-driven approach.
4.1 Toward a Targeted Pharmacovigilance Approach
Although it is challenging to identify safer molecules
within therapeutic classes, several efforts have been made
to provide comprehensive lists of drugs with recognized or
potential TdP liability [52]. Because of the compelling
clinical need, this aspect is starting to be critically con-
sidered in pharmacovigilance. For instance, a recent study
on Stevens-Johnson syndrome/toxic epidermal necrolysis
underlined several drugs with no association, which may be
considered as alternative treatment options [53].
Although actual ranking of risk cannot be achieved
through spontaneous reports, the extent of consumption
and time on the market should also be taken into account
when interpreting pharmacovigilance data (targeted
pharmacovigilance).
Based on these criteria and our results, three provisional
classes of risk could be proposed: APs with a potential
torsadogenic risk (i.e., if a significant disproportionality is
found for TdP/QT and consistently persists across all
analyses, including the intraclass approach); APs with
uncertain torsadogenic risk (i.e., no consistency across
disproportionality analyses and low use or very recent
entry on the market); and APs with a probably lower risk of
torsadogenicity (i.e., consistent absence of significant dis-
proportionality across analyses, high use, and long market
life). Within the first class, only the following APs can be
included: amisulpride, haloperidol, and ziprasidone. No
drug used to treat psychosis can be included at the moment
in the lower risk class. All other APs should be included in
the uncertain class, either because of the inconsistency
among disproportionality results or because of the limited
marketing penetration.
We believe that, for practical reasons, the AZCERT
website represents the most authoritative source of data
regarding the risk of drug-induced TdP, especially as rapid
screening for physicians. However, this resource appears to
adopt a very precautionary attitude in line with the
approach of regulators (e.g., moxifloxacin is now reported
in List 1 despite being largely used as a comparator in
thorough QT studies; citalopram is now included in List 1
after a warning was posted by the European Medicines
Agency), thus causing a steady increase in the number of
torsadogenic drugs. The website even explicitly mentioned
that ‘‘The absence of a drug from these lists should not be
considered an indication that they are free of risk of QT
prolongation or torsades de pointes’’ [30]. The AZCERT
Advisory Board should implement available lists by iden-
tifying possible therapeutic alternatives within the main
pharmacological classes to be used in patients susceptible
to TdP.
5 Conclusion
This pharmacovigilance analysis on the FAERS identified
three torsadogenic signals, which were neither mentioned
by the 2011 AZCERT classification nor arose from previ-
ous literature data: amisulpride, cyamemazine, and olan-
zapine. Our findings should be considered with caution,
because they need to be validated by integrating data from
sources of clinical data. In addition, for more recently
marketed drugs, which may be channelled to patients at
high risk of TdP, careful monitoring should be maintained.
As a matter of fact, the imperfect predictivity of in vitro/
in vivo assays and thorough QT studies strengthens the role
of postmarketing surveillance in early and timely detection
of safety signals.
We believe that the proposed strategy to identify signals
is of interest for regulators, as a tool to implement routine
pharmacovigilance activity in prioritizing safety issues. On
the other hand, our findings represent per se a preliminary
contribution for clinicians in prescribing or switching
between APs, especially in the clinical setting of poly-
pharmacy, where drug–drug interactions may increase the
likelihood of TdP occurrence in susceptible patients.
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